GM-CSF has been approved for treatment of neutropenia due to myelosuppressive chemotherapy or bone marrow transplantation, peripheral blood stem cell mobilization, graft failure and induction therapy for acute myelogenous leukemia (AML) (3). This evidence concerns the gene CSF2 and acute myeloid leukemia.